PPARA; PPARD; PPARG; | |
NR0B1; | |
NR3C1; | |
AKR1B10; AKR1B1; HSD17B10; ALOX15; ALDH1A1; USP2; | |
HIF1A; | |
SLC6A2; SLC6A3; SLCO1B3; SLCO1B1; | |
LMNA; RAB9A; NPC1; PAX8; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.173E-09 | 2.366E-05 | AKR1B1, AKR1B10, CYP2C19, CYP2C9, CYP3A4, NPC1, NR0B1, PPARD |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.067E-08 | 1.165E-04 | CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.334E-07 | 3.910E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.335E-07 | 6.833E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.633E-07 | 7.602E-04 | CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.333E-06 | 1.160E-03 | NR0B1, NR3C1, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.905E-06 | 2.028E-03 | AKR1B1, AKR1B10, ALDH1A1, CYP3A4, NPC1, PPARD |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.704E-06 | 2.372E-03 | NR0B1, NR3C1, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 4.346E-06 | 2.629E-03 | ALOX15, CYP2C19, CYP2C9, PPARA, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.739E-06 | 3.204E-03 | NR0B1, NR3C1, PPARA, PPARD, PPARG |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.240E-03 | 4.879E-03 | AKR1B10; AKR1B1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 9.801E-04 | 4.131E-03 | AKR1B10; AKR1B1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.611E-04 | 3.908E-03 | AKR1B10; AKR1B1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.300E-03 | 1.145E-02 | AKR1B10; AKR1B1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.787E-05 | 1.135E-03 | CYP2C9; ALOX15; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.255E-08 | 2.435E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.127E-04 | 1.135E-03 | CYP2C9; ALDH1A1; CYP3A4 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.372E-09 | 4.939E-07 | CA12; CA2; CA4; CA7 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.006E-03 | 1.641E-02 | CYP2C9; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.347E-04 | 1.135E-03 | CYP2C9; CYP3A4; CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1 |
C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; NR3C1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |